[B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice].
Ramos-Casals
Manuel
M
Laboratorio de Enfermedades Autoinmunes «Josep Font», Instituto de Investigaciones Biomédicas August Pi i Sunyer, Hospital Clínic, Barcelona, España. mramos@clinic.ub.es
Díaz-Lagares
Cándido
C
Khamashta
Munther A
MA
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects; D001327:Autoimmune Diseases / Q000628:therapy*; D001402:B-Lymphocytes; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D008212:Lymphocyte Depletion / Q000009:adverse effects / Q000592:standards; D012008:Recurrence; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab